Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Colchicine pre-PCI improves biomarkers, not injury risk

Key clinical point: Oral colchicine before percutaneous coronary intervention has no preventive effect, compared with placebo.

Major finding: Rates of PCI-related myocardial injury were 57.3% and 64.2% in the colchicine and placebo groups, respectively.

Study details: Investigator-initiated, single-site prospective randomized double-blind study of 400 patients from COLCHICINE-PCI trial randomized to treatment or placebo.

Disclosures: Dr. Shah disclosed financial relationships with Phillips Volcano and Radux. The VA Office of Research and Development and AHA provided grant funding and Takeda provided the drug.


Shah B. AHA 2019, Late Breaking Science session IV.